Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

Pharmacological strategies to prevent SARS-CoV-2 infection and to treat the early phases of COVID-19 disease

(2021) Lucia Scarabel et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

(2021) Kevin R. Bewley et al.   Nature Protocols

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

(2020) Ludivine Grzelak et al.   Science Translational Medicine

Emerging Concepts and Technologies in Vaccine Development

(2020) Morgan Brisse et al.   Frontiers in Immunology

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Recent Insights into Emerging Coronavirus: SARS-CoV-2

(2020) Zifang Shang et al.   ACS Infectious Diseases

Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot

(2019) Mathieu Mateo et al.   Science Translational Medicine

Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model

(2018) Bianca S. Bodmer et al.   VIROLOGY

A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model

(2018) Cindy Nürnberger et al.   JOURNAL OF VIROLOGY

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial

(2018) Emil C Reisinger et al.   LANCET

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial

(2015) Katrin Ramsauer et al.   LANCET INFECTIOUS DISEASES

Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein

(2014) Nicolas Escriou et al.   VIROLOGY

A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

(2013) Samantha Brandler et al.   VACCINE

Measles Vaccine Expressing the Secreted Form of West Nile Virus Envelope Glycoprotein Induces Protective Immunity in Squirrel Monkeys, a New Model of West Nile Virus Infection

(2012) Samantha Brandler et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity of a Recombinant Measles-HIV-1 Clade B Candidate Vaccine

(2012) Richard Stebbings et al.   PLoS One